Pfizer, the world’s biggest drugmaker, must be counting its bets on the passage of the controversial Korea-US Free Trade Agreement, as it will be investing a total of $300 million in South Korea by 2012.Pfizer may think of this as an expansion opportunity, but Koreans’ access to universal healthcare and low-cost medicine is threatened by the Korea-US FTA, as if passed, it will raise the price of pharmaceutical drugs. See "Debunking Five Myths about Korea-US FTA."
No comments:
Post a Comment